Jul. 10 at 3:19 PM
$VERA CEO Marshall Fordyce sold 46,250 shares, but this was executed under a prearranged Rule 10b5-1 trading plan adopted on 9 January 2026, around six months before the transaction. He still holds roughly 374,000 shares directly and through trusts, so this was not a full exit or sudden dump after FDA approval. The timing creates poor optics, but the filing itself looks more like planned diversification than a clear negative signal about Vera’s fundamentals 🤦
